Neuronetics Comments on Letter from Pointillist Family Office
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) responded to a public letter from Jorey Chernett at Pointillist Family Office dated April 6, 2026. The Company said the Board and management are committed to acting in all shareholders' best interests and regularly evaluate options to maximize shareholder value.
According to the Company, the Board reviewed the letter, values engagement with shareholders, and agrees the current valuation may not reflect the business strength; the Board is open to constructive engagement while executing strategic priorities to enhance long-term value.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – STIM
On the day this news was published, STIM declined 10.23%, reflecting a significant negative market reaction. Argus tracked a trough of -15.5% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $121.93M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
STIM gained 15.79% while peers were mixed: BSGM +39.91%, CVRX +0.44%, ELMD +1.94%, TLSI -3.09%, BWAY -7.5%. Momentum scanner shows mixed moves (CERS +3.24%, INGN +2.04%, CATX -6.39%), reinforcing a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Q4/FY25 earnings | Neutral | -9.9% | Reported strong revenue growth, lower margins, and a sizeable annual net loss. |
| Mar 17 | CEO transition | Positive | -9.9% | Named new President and CEO with RSU grant vesting over three years. |
| Mar 03 | Earnings date set | Neutral | -1.6% | Announced date and time for Q4 2025 earnings release and conference call. |
| Feb 10 | Prelim earnings | Positive | +23.3% | Preliminary Q4/FY25 results with strong revenue growth and positive operating cash flow. |
| Nov 20 | Conference appearance | Neutral | -12.8% | Planned participation in a Piper Sandler healthcare conference fireside chat. |
News often triggers sizable moves for STIM, with both positive and negative reactions to corporate updates and events.
Over the last six months, Neuronetics reported strong growth, with Q4 2025 revenue $41.8M and FY2025 revenue $149.2M, but also a $39.1M net loss and lower gross margins. Preliminary results on Feb 10, 2026 were followed by a +23.29% move, while the full Q4/FY release on Mar 17, 2026 and concurrent CEO appointment coincided with a -9.93% reaction. Earlier, a conference appearance on Nov 20, 2025 saw a -12.75% move, underscoring volatile responses to news.
Regulatory & Risk Context
An effective shelf registration dated March 17, 2026 covers resale of up to 20,737,061 shares of common stock by selling stockholders. The company will receive no proceeds from these sales, and the filing notes that concurrent sales of a significant share block could affect the market price.
Market Pulse Summary
The stock dropped -10.2% in the session following this news. A negative reaction despite the Board’s constructive response to the Pointillist Family Office letter would fit the pattern of volatile moves around corporate events. Recent history shows sizeable swings around earnings and leadership changes, and a resale shelf for more than 20.7M shares adds potential supply overhang. Investors have also navigated leadership transitions and cost-reduction plans disclosed in recent 8-K filings.
AI-generated analysis. Not financial advice.
MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company’s Board of Directors (the “Board”) from Jorey Chernett at Pointillist Family Office published on April 6, 2026:
The Board and management team are committed to acting in the best interests of all shareholders and regularly evaluate opportunities to maximize shareholder value. The Board has reviewed Mr. Chernett’s letter and appreciates his engagement and dialogue as a shareholder.
The Company agrees with Mr. Chernett that the current valuation does not fully reflect the strength of the Company’s business, and the Board is open to constructive engagement with its shareholders as the Company executes on its strategic priorities to enhance long-term value.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal years, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to maintain positive cash flow. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
Devin Broda
ICR
Devin.Broda@icrinc.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
